Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy

Mount Sinai Journal of Medicine

Volumn 74, Issue 1, 2007, Pages 7-14

  Kieburtz, Karl ^a   Olanow, C Warren ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Experimental therapeutics; Translational science

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; MONOCLONAL ANTIBODY CD28; NEUROPROTECTIVE AGENT; PLACEBO; TCH 346; TGN 1412; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MARKETING; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TOLERANCE; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; EXPERIMENTAL MODEL; EXPERIMENTAL THERAPY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HUMAN; HYPOTENSION; IN VITRO STUDY; INFLAMMATION; INTERVENTION STUDY; KIDNEY FAILURE; LUNG INFILTRATE; NEUROPROTECTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; REVIEW; SINGLE DRUG DOSE; TOXICOLOGY;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; SAFE SEX; THERAPEUTICS;

EID: 34250734052     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20006     Document Type: Review

References (25)

1. Ioannidis JPA. Evolution and translation of research findings: from bench to where? PLoS Clin Trials 2006; 1(7): e36. DOI: 10.1371/ journal.pctr.0010036.
2. Sun Q, Wang A, Jin X, et al. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA 2005; 294: 3003-3010.
3. Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 2005; 39: 153-171.
4. Artal-Sanz M, de Jong L, Tavernarakis N. Caenorhabditis elegans: a versatile platform for drug discovery. Biotechnol J 2006; 1: 1405-1418.
5. Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281:1851-1854.
6. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F ß-amyloid precursor protein. Nature 1995; 373: 523-527.
7. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 19961; 87: 493-506.
8. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347-350.
9. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437-445.
10. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656-1661.
11. Melrose HL, Lincoln SJ, Tyndall GM, Farrer MJ. Parkinson's disease: a rethink of rodent models. Exp Brain Res 2006; 173: 196-204.
12. Gimenez-Llort L, Blazquez G, Canete T, et al. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007; 31: 125-147.
13. Department of Health and Human Services, Food and Drug Administration. International conference on harmonisation: guidance on general considerations for clinical trials. Fed Regist 1997; 62: 66113-66119.
14. Hermann DM, Ertugrul K, Spudich A, et al. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006; 60: 489-498.
15. Raucy JL, Allen SW. Recent advances in P450 research. Pharmacogenomics J 2001; 1: 178-186.
16. Lee MD, Ayanoglu E, Gong L. Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions. Xenobiotica 2006; 36(10-11): 1013-1080.
17. Hancox JC, Mitcheson JS. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br J Pharmacol 2006; 149: 457-459.
18. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006; 164: 881-889.
19. Zerhouni E. Policy forum: the NIH roadmap. Science 2003; 302:, 63-64 72.
20. Zerhouni EA. US biomedical research: basic, translational, and clinical sciences. JAMA 2005; 294: 1352-1358.
21. Hurko O, Ryan JL. Translational research in central nervous system drug discovery. NeuroRx® 2005; 2: 671-682.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 7, 2005; J: I'GUIDANCE 5541fnlclnl.docl 1-27.
23. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
24. Olanow CW, Schapira AHV, Lewitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006; 5: 1013-1020.
25. Schapira AHV, Olanow CW. Neuroprotection in Parkinson's disease: Myths, mysteries, and misconceptions. JAMA 2004; 291: 358-364.